Search Results Search Sort by RelevanceMost Recent Policy Forum Apr 2019 How Should Engineered Nanomaterials Be Regulated for Public and Environmental Health? David B. Resnik, JD, PhD Minimizing and managing risks of ENMs means considering whether and when existing legal frameworks offer sufficient protection. AMA J Ethics. 2019;21(4):E363-369. doi: 10.1001/amajethics.2019.363. Health Law Apr 2019 Regulating Nanomedicine at the Food and Drug Administration Jordan Paradise, JD Nanoscale products pose ethical, legal, and policy challenges to governing the use of products that integrate multiple mechanisms of therapeutic action. AMA J Ethics. 2019;21(4):E347-355. doi: 10.1001/amajethics.2019.347. Medicine and Society Nov 2019 What Are Good Guidelines for Evaluating Uterus Transplantation? Margaret Horvat, MA and Ana Iltis, PhD Recent advances in UTx suggest it is on a trajectory toward becoming an accepted clinical practice to treat absolute uterine factor infertility. AMA J Ethics. 2019;21(11):E988-995. doi: 10.1001/amajethics.2019.988. Medicine and Society Nov 2019 What Hand Transplantation Teaches Us About Embodiment Brock Bahler, PhD Current QoL conversations in HTx could be enhanced by a phenomenological account of temporality, embodiment, and intersubjectivity. AMA J Ethics. 2019;21(11):E996-1002. doi: 10.1001/amajethics.2019.996. Policy Forum Nov 2019 Why Quality-of-Life Data Collection and Use Should Be Standardized When Evaluating Candidates for Hand Transplantation Martin Kumnig, PhD, MSc, Emma K. Massey, PhD, and Lisa S. Parker, PhD Improving candidate evaluation and informed consent is key to motivating authenticity, not just voluntariness. AMA J Ethics. 2019;21(11):E974-979. doi: 10.1001/amajethics.2019.974. Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021. Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036. Policy Forum Dec 2019 How Should Gene Editing Be Managed by Risk Managers? David Sine, D.Bioethics Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies. AMA J Ethics. 2019;21(12):E1059-1064. doi: 10.1001/amajethics.2019.1059. State of the Art and Science Feb 2017 Reasonableness, Credibility, and Clinical Disagreement Mary Jean Walker, PhD and Wendy A. Rogers, BMBS, PhD When is a source credible and how do beliefs about a source’s credibility influence assessments of evidence? AMA J Ethics. 2017;19(2):176-182. doi: 10.1001/journalofethics.2017.19.2.stas1-1702. Policy Forum Feb 2017 What Is the Relevance of Procedural Fairness to Making Determinations about Medical Evidence? Govind Persad, JD, PhD Procedures for weighing factual evidence could help avoid the epistemic injustice of discounting or ignoring the voices of clinical research subjects. AMA J Ethics. 2017;19(2):183-191. doi: 10.1001/journalofethics.2017.19.2.pfor1-1702. Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Policy Forum Apr 2019 How Should Engineered Nanomaterials Be Regulated for Public and Environmental Health? David B. Resnik, JD, PhD Minimizing and managing risks of ENMs means considering whether and when existing legal frameworks offer sufficient protection. AMA J Ethics. 2019;21(4):E363-369. doi: 10.1001/amajethics.2019.363.
Health Law Apr 2019 Regulating Nanomedicine at the Food and Drug Administration Jordan Paradise, JD Nanoscale products pose ethical, legal, and policy challenges to governing the use of products that integrate multiple mechanisms of therapeutic action. AMA J Ethics. 2019;21(4):E347-355. doi: 10.1001/amajethics.2019.347.
Medicine and Society Nov 2019 What Are Good Guidelines for Evaluating Uterus Transplantation? Margaret Horvat, MA and Ana Iltis, PhD Recent advances in UTx suggest it is on a trajectory toward becoming an accepted clinical practice to treat absolute uterine factor infertility. AMA J Ethics. 2019;21(11):E988-995. doi: 10.1001/amajethics.2019.988.
Medicine and Society Nov 2019 What Hand Transplantation Teaches Us About Embodiment Brock Bahler, PhD Current QoL conversations in HTx could be enhanced by a phenomenological account of temporality, embodiment, and intersubjectivity. AMA J Ethics. 2019;21(11):E996-1002. doi: 10.1001/amajethics.2019.996.
Policy Forum Nov 2019 Why Quality-of-Life Data Collection and Use Should Be Standardized When Evaluating Candidates for Hand Transplantation Martin Kumnig, PhD, MSc, Emma K. Massey, PhD, and Lisa S. Parker, PhD Improving candidate evaluation and informed consent is key to motivating authenticity, not just voluntariness. AMA J Ethics. 2019;21(11):E974-979. doi: 10.1001/amajethics.2019.974.
Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021.
Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036.
Policy Forum Dec 2019 How Should Gene Editing Be Managed by Risk Managers? David Sine, D.Bioethics Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies. AMA J Ethics. 2019;21(12):E1059-1064. doi: 10.1001/amajethics.2019.1059.
State of the Art and Science Feb 2017 Reasonableness, Credibility, and Clinical Disagreement Mary Jean Walker, PhD and Wendy A. Rogers, BMBS, PhD When is a source credible and how do beliefs about a source’s credibility influence assessments of evidence? AMA J Ethics. 2017;19(2):176-182. doi: 10.1001/journalofethics.2017.19.2.stas1-1702.
Policy Forum Feb 2017 What Is the Relevance of Procedural Fairness to Making Determinations about Medical Evidence? Govind Persad, JD, PhD Procedures for weighing factual evidence could help avoid the epistemic injustice of discounting or ignoring the voices of clinical research subjects. AMA J Ethics. 2017;19(2):183-191. doi: 10.1001/journalofethics.2017.19.2.pfor1-1702.